| Name | Title | Contact Details |
|---|---|---|
John Northcott |
Chief Commercial Officer | Profile |
Andrew Sargent |
Senior Director, IT R&D and Clinical Systems | Profile |
Jing Tao |
Director, Formulation R&D | Profile |
Roy Haskell |
Executive Director, Formulation R&D | Profile |
John Houston |
President of R&D | Profile |
NeruoGenomeX, Inc. is a Malvern, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how
The Institute for Athletic Medicine is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LamdaGen Corp is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
We are a global provider of drug development and discovery services, encompassing drug substance, drug product, bioanalysis, and CMC regulatory services across small molecules, large molecules, and nanomedicines. Our six international locations offer comprehensive CDMO and BioAnalytical CRO services to a wide range of clients worldwide. We recognize the intricate challenges associated with advancing a promising molecule from the laboratory to the patient. Our multidisciplinary team is eager to collaborate with you throughout your development process, utilizing specialized technologies to optimize formulation and manufacturing. We possess extensive expertise in spray drying, hot melt extrusion, and lipid-based formulations that enhance bioavailability and solubility. Additionally, our capabilities include polymeric, metal, and lipid nanoparticles for advanced drug delivery applications, as well as high-potency and controlled substance handling for highly specialized therapeutics. At Ardena, all work adheres to the appropriate regulatory standards as you progress through the clinical development pathway. Please contact us to further discuss your clinical and scientific objectives and explore how we can work together.